Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonatan Salzer

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Brain : a Journal of Neurology|November 6, 2023
Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosisViktor Grut, Martin Biström, Jonatan Salzer, et al.
European Journal of Neurology|June 9, 2021
Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis-a presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
The Lancet. Neurology|July 16, 2022
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trialAnders Svenningsson, Thomas Frisell, Joachim Burman, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Brain : a Journal of Neurology|November 6, 2023
Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosisViktor Grut, Martin Biström, Jonatan Salzer, et al.
European Journal of Neurology|June 9, 2021
Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis-a presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
The Lancet. Neurology|July 16, 2022
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trialAnders Svenningsson, Thomas Frisell, Joachim Burman, et al.
Pageof 5